416 related articles for article (PubMed ID: 25924765)
21. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
[TBL] [Abstract][Full Text] [Related]
22. Clostridium difficile antibodies: a patent evaluation (WO2013028810).
Lo Vecchio A; Della Ventura B; Nicastro E
Expert Opin Ther Pat; 2013 Dec; 23(12):1635-40. PubMed ID: 23978053
[TBL] [Abstract][Full Text] [Related]
23. Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM
N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970
[TBL] [Abstract][Full Text] [Related]
24. Development of a Novel Vaccine Containing Binary Toxin for the Prevention of Clostridium difficile Disease with Enhanced Efficacy against NAP1 Strains.
Secore S; Wang S; Doughtry J; Xie J; Miezeiewski M; Rustandi RR; Horton M; Xoconostle R; Wang B; Lancaster C; Kristopeit A; Wang SC; Christanti S; Vitelli S; Gentile MP; Goerke A; Skinner J; Strable E; Thiriot DS; Bodmer JL; Heinrichs JH
PLoS One; 2017; 12(1):e0170640. PubMed ID: 28125650
[TBL] [Abstract][Full Text] [Related]
25. Immune-based treatment and prevention of Clostridium difficile infection.
Zhao S; Ghose-Paul C; Zhang K; Tzipori S; Sun X
Hum Vaccin Immunother; 2014; 10(12):3522-30. PubMed ID: 25668664
[TBL] [Abstract][Full Text] [Related]
26. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.
Siddiqui F; O'Connor JR; Nagaro K; Cheknis A; Sambol SP; Vedantam G; Gerding DN; Johnson S
J Infect Dis; 2012 Jan; 205(1):128-33. PubMed ID: 22124129
[TBL] [Abstract][Full Text] [Related]
27. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.
Marozsan AJ; Ma D; Nagashima KA; Kennedy BJ; Kang YK; Arrigale RR; Donovan GP; Magargal WW; Maddon PJ; Olson WC
J Infect Dis; 2012 Sep; 206(5):706-13. PubMed ID: 22732923
[TBL] [Abstract][Full Text] [Related]
28. Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B.
Chen W; Liu WE; Li YM; Luo S; Zhong YM
Mol Med Rep; 2015 Nov; 12(5):7712-20. PubMed ID: 26459027
[TBL] [Abstract][Full Text] [Related]
29. Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B.
Devera TS; Lang GA; Lanis JM; Rampuria P; Gilmore CL; James JA; Ballard JD; Lang ML
Infect Immun; 2016 Jan; 84(1):194-204. PubMed ID: 26502913
[TBL] [Abstract][Full Text] [Related]
30. Intravenous adenovirus expressing a multi-specific, single-domain antibody neutralizing TcdA and TcdB protects mice from Clostridium difficile infection.
Yang Z; Shi L; Yu H; Zhang Y; Chen K; Saint Fleur A; Bai G; Feng H
Pathog Dis; 2016 Oct; 74(7):. PubMed ID: 27502696
[TBL] [Abstract][Full Text] [Related]
31. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
[TBL] [Abstract][Full Text] [Related]
32. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
Koon HW; Shih DQ; Hing TC; Yoo JH; Ho S; Chen X; Kelly CP; Targan SR; Pothoulakis C
Antimicrob Agents Chemother; 2013 Jul; 57(7):3214-23. PubMed ID: 23629713
[TBL] [Abstract][Full Text] [Related]
33. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.
Gerding DN
Discov Med; 2012 Jan; 13(68):75-83. PubMed ID: 22284786
[TBL] [Abstract][Full Text] [Related]
34. Active and passive immunization against Clostridium difficile diarrhea and colitis.
Giannasca PJ; Warny M
Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Chicken IgY Specific to
Pizarro-Guajardo M; Díaz-González F; Álvarez-Lobos M; Paredes-Sabja D
Front Cell Infect Microbiol; 2017; 7():365. PubMed ID: 28856119
[No Abstract] [Full Text] [Related]
36. Clostridium difficile--beyond antibiotics.
Kyne L
N Engl J Med; 2010 Jan; 362(3):264-5. PubMed ID: 20089977
[No Abstract] [Full Text] [Related]
37. Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.
Wang Y; Wang S; Bouillaut L; Li C; Duan Z; Zhang K; Ju X; Tzipori S; Sonenshein AL; Sun X
Infect Immun; 2018 Nov; 86(11):. PubMed ID: 30150259
[TBL] [Abstract][Full Text] [Related]
38. Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.
Lamont JT
Trans Am Clin Climatol Assoc; 2002; 113():167-80; discussion 180-1. PubMed ID: 12053708
[TBL] [Abstract][Full Text] [Related]
39. Immunogenic properties of the surface layer precursor of Clostridium difficile and vaccination assays in animal models.
Bruxelle JF; Mizrahi A; Hoys S; Collignon A; Janoir C; Péchiné S
Anaerobe; 2016 Feb; 37():78-84. PubMed ID: 26505926
[TBL] [Abstract][Full Text] [Related]
40. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.
Borriello SP; Ketley JM; Mitchell TJ; Barclay FE; Welch AR; Price AB; Stephen J
J Med Microbiol; 1987 Aug; 24(1):53-64. PubMed ID: 3612744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
